EUCTR2006-006373-25-FI进行中（未招募）不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/A
Pfizer Inc. 235 East 42nd Street, New York, NY100170 个研究点目标入组 300 人开始时间: 2009年6月16日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Evidence of a signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
- •Subject has received at least one dose of study drug and has discontinued participation in any Phase 2B or 3 randomized, controlled, or open label (qualifying study) of CP 690,550 for the treatment of RA.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any subject who refuses to provide consent.
研究者
相似试验
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-ATPfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK300
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-SEPfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK300
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-CZPfizer Inc. 235 East 42nd Street, New York, NY10017300
进行中（未招募）
不适用
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF cp 690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2006-006373-25-BGPfizer Inc. 235 East 42nd Street, New York, NY10017300
进行中（未招募）
1 期
A PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE LONG TERM SAFETY AND FUNCTIONAL STATUS OF SUBJECTS WITH RHEUMATOID ARTHRITIS PREVIOUSLY ENROLLED IN STUDIES OF CP-690,550 - N/ACP 690,550 is being developed as a disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA).MedDRA version: 8.1 Level: LLT Classification code 10039073 Term: Rheumatoid arthritisEUCTR2006-006373-25-GBPfizer Inc. 235 East 42nd Street, New York, NY10017300